Angeliq Regulatory Post Marketing Surveillance

Inclusion Criteria: * Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women more than 1 year postmenopause * Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis Exclusion Criteria: * Undiagnosed genital bleeding * Known, past or suspected cancer of the breast * Known or suspected estrogen-dependent malignant tumors (e.g. endometrial cancer) * Untreated endometrial hyperplasia * Previous idiopathic or current venous thromboembolism (e.g. deep venous thrombosis, pulmonary embolism) * Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction) * Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal * Porphyria * Severe renal insufficiency or acute renal failure * Known hypersensitivity to the active substances or to any of the excipients